WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

THE PREVALENCE OF CARDIOVASCULAR COMORBIDITIES IN COVID-19 HOSPITALIZED PATIENTS

Nikola Maleševi?* MD, Goran Bokan MD, Saša Lon?ar and MD Vlado ?aji? MD, PhD

ABSTRACT

Background: COVID-19 infection, or infection caused by coronavirus, has reached millions of cases worldwide and is currently a global health and socioeconomic problem. The range of clinical presentation of COVID-19 infection is very wide. The spectrum of respiratory symptoms is dominant in productive symptomatology. The severity of the clinical presentation as well as the prognosis of the disease depends on the associated comorbidities. Cardiovascular comorbidities have been shown to be the most significant and most frequent ones. Methods: The research was designed as an observational, retrospective study. The observed sample consisted of consecutive, hospitalized patients at the Infectious Diseases Clinic, at the University Clinical Center of the Republic of Srpska, from the 1st March to 15th August, 2020 with proven COVID-19 infection (positive real time PCR test). In this study we used clinical and epidemiological datas from 265 Discharge Letters archived in the Clinical Information System. Results: The mean age of patients with COVID-19 was 54.99 years, with a predominance of males (61.88%). The most common cardiovascular comorbidity was hypertension with a prevalence of 43% in relation to the total number of hospitalized, and 72.15% in relation to the total number of all cardiovascular comorbidities. Two patients were diagnosed with acute myocardial infarction that ended in death. The second most common cardiovascular comorbidity was cardiomyopathy - in 23 patients, or 8.68% of the total number of hospitalized. Conclusion: Cardiovascular comorbidities were present in almost 2/3 of hospitalized patients. Accordingly, it is very important to consider the prevalence of cardiovascular comorbidities and their effects on the course of the disease in patients with proven COVID-19 infection.

Keywords: cardiovascular comorbidities, coronavirus, COVID-19, hypertension.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More